Cara Therapeutics 8-K SEC Filing Reveals Merger Plans with Tvardi Therapeutics

Cara Therapeutics, Inc., a Delaware corporation, disclosed in its recent 8-K SEC filing dated January 16, 2025, its plans to merge with Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in developing oral, small molecule therapies targeting STAT3 to address fibrosis-driven diseases with unmet medical needs.

The merger agreement, titled the Agreement and Plan of Merger and Reorganization, was signed on December 17, 2024. This agreement involves the merger of Cara Therapeutics’ subsidiary, CT Convergence Merger Sub Inc., with Tvardi, with Tvardi surviving as a wholly-owned subsidiary of Cara Therapeutics. The merger, subject to stockholder approval and customary closing conditions, aims to establish a combined company focused on advancing the development of Tvardi’s programs.

Included in the filing is an investor presentation (Exhibit 99.1) which will be shared with potential investors of Tvardi and the post-merger company. The disclosed information falls under Regulation FD Disclosure, and it has been emphasized that the content is furnished and not filed for formal purposes under the Securities Exchange Act of 1934.

The filing also reiterated a cautionary statement regarding forward-looking statements, recognizing the inherent risks and uncertainties that could affect actual results. This disclosure aligns with previous announcements by the company regarding strategic alternatives initiated in July 2024.

Additionally, Cara Therapeutics highlighted that certain regulatory filings have been made with the Securities and Exchange Commission (SEC) in connection with the proposed merger. Stockholders and investors are urged to review these materials in full to understand the implications of the proposed transaction.

The proposed acquisition is expected to provide a significant push to both companies’ research and development efforts, particularly in addressing fibrosis-driven diseases. The disclosure outlines a promising future for the combined entity, with a strong capital base expected following the completion of the merger and subsequent financing activities.

The 8-K filing from Cara Therapeutics underscores a significant move in the biopharmaceutical industry, positioning the company for enhanced capabilities in targeting fibrosis-driven diseases through the merger with Tvardi Therapeutics.

Please note that the above information is based on the contents of the 8-K SEC filing by Cara Therapeutics, and readers are encouraged to refer to the original document for full details.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Cara Therapeutics’s 8K filing here.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.